Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro

Simple item page
dc.contributor.authorPaz Ocaranza, Maria
dc.contributor.authorLavandero, Sergio
dc.contributor.authorJalil, Jorge E.
dc.contributor.authorMoya, Jaqueline
dc.contributor.authorPinto, Melissa
dc.contributor.authorNovoa, Ulises
dc.contributor.authorApablaza, Felipe
dc.contributor.authorGonzalez, Leticia
dc.contributor.authorHernandez, Carol
dc.contributor.authorVaras, Manuel
dc.contributor.authorLopez, Rene
dc.contributor.authorGodoy, Ivan
dc.contributor.authorVerdejo, Hugo
dc.contributor.authorChiong, Mario
dc.date.accessioned2024-01-10T12:37:34Z
dc.date.available2024-01-10T12:37:34Z
dc.date.issued2010
dc.description.abstractBackground Angiotensin-(1-9) is present in human and rat plasma and its circulating levels increased early after myocardial infarction or in animals treated with angiotensin-converting enzyme inhibitor. However, the cardiovascular effects of this peptide are unknown.
dc.description.abstractObjective To determine whether angiotensin-(1-9) is a novel anti-cardiac hypertrophy factor in vitro and in vivo and whether this peptide is involved in the pharmacological effects of cardiovascular drugs acting on the renin-angiotensin system.
dc.description.abstractMethods and results The administration of angiotensin(1-9) to myocardial infarcted rats by osmotic minipumps (450 ng/kg per min, n=6) vs. vehicle (n=8) for 2 weeks decreased plasma angiotensin II levels, inhibited angiotensin- converting enzyme activity and also prevented cardiac myocyte hypertrophy. However, cardiac myocyte hypertrophy attenuation triggered by angiotensin-(1-9) was not modified with the simultaneous administration of the angiotensin-(1-7) receptor antagonist A779 (100 ng/kg per min, n=6). In experiments in vitro with cultured cardiac myocytes incubated with norepinephrine (10 mu mol/l) or with insulin-like growth factor-1 (10 nmol/l), angiotensin(1-9) also prevented hypertrophy. In other experimental setting, myocardial infarcted rats (n=37) were randomized to receive either vehicle (n=12), enalapril (10 mg/kg per day, n=12) or angiotensin II receptor blocker candesartan (10 mg/kg per day, n=13) for 8 weeks. Both drugs prevented left ventricle hypertrophy and increased plasma angiotensin-(1-9) levels by several folds. Angiotensin-(1-9) levels correlated negatively with different left ventricular hypertrophy markers even after adjustment for blood pressure reduction.
dc.description.abstractConclusion Angiotensin-(1-9) is an effective and a novel anti-cardiac hypertrophy agent not acting via the Mas receptor. J Hypertens 28:1054-1064 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
dc.description.funderComision Nacional de Ciencia y Tecnologia (CONICYT), Chile
dc.fechaingreso.objetodigital2024-05-22
dc.format.extent11 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1097/HJH.0b013e328335d291
dc.identifier.eissn1473-5598
dc.identifier.issn0263-6352
dc.identifier.pubmedidMEDLINE:20411619
dc.identifier.urihttps://doi.org/10.1097/HJH.0b013e328335d291
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76878
dc.identifier.wosidWOS:000276706500025
dc.information.autorucMedicina;Apablaza F;S/I;5554
dc.information.autorucMedicina;Godoy I;S/I;70048
dc.information.autorucCiencias Biológicas;Hernández C;S/I;149722
dc.information.autorucMedicina;Jalil J;S/I;99946
dc.information.autorucMedicina;López R;S/I;156224
dc.information.autorucCiencias Biológicas;Novoa U;S/I;1000353
dc.information.autorucMedicina;Ocaranza MP;S/I;1001254
dc.information.autorucCiencias Biológicas;Varas M;S/I;104036
dc.information.autorucMedicina;Verdejo H;S/I;1001175
dc.issue.numero5
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final1064
dc.pagina.inicio1054
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.revistaJOURNAL OF HYPERTENSION
dc.rightsacceso restringido
dc.subjectangiotensin-converting enzyme 2
dc.subjectangiotensin-(1-9)
dc.subjectcardiac dysfunction
dc.subjectcardiac hypertrophy
dc.subjectcardiac myocyte
dc.subjectmyocardial infarction
dc.subjectCONVERTING-ENZYME
dc.subjectSYSTEM
dc.subjectRENIN
dc.subjectHEART
dc.subjectHYDROLYSIS
dc.subjectDYSFUNCTION
dc.subjectINHIBITION
dc.subjectPREVENTION
dc.subjectPEPTIDES
dc.subjectPATHWAYS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAngiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro
dc.typeartículo
dc.volumen28
sipa.codpersvinculados5554
sipa.codpersvinculados70048
sipa.codpersvinculados149722
sipa.codpersvinculados99946
sipa.codpersvinculados156224
sipa.codpersvinculados1000353
sipa.codpersvinculados1001254
sipa.codpersvinculados104036
sipa.codpersvinculados1001175
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro.pdf
Size:
3.29 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas